Skip to main content

Table 1 Studies on clinical effectiveness of omalizumab in patients with severe asthma

From: Biomarkers and severe asthma: a critical appraisal

Mediators and parameters Biologic sample/procedure Patients Effects of omalizumab treatment References
ET-1
FeNO
ECP
Eosinophils count
FEV1
EBC
EB
Blood
Blood
Spirometry
19 severe asthmatics
9/19 omalizumab (+)




[32]
RANTES/CCL5
FeNO
ECP
Eosinophils count
EBC
EB
Blood
Blood
19 severe asthmatics
9/19 omalizumab (+)



[33]
Eosinophils count Blood 13 severe sthmatics
13/13 omalizumab (+)
[34]
Quality of life
PEF
Unscheduled visits
Exacerbations
FeNO
CalvNO
Eosinophils count
Airway-wall thickness
Questionnaire
Spirometry
Clinical data
Clinical data
EB
EB
Sputum
CT
26 severe asthmatics
26/26 omalizumab (+)







[35]
Exacerbations
Systemic steroids
ACT score
Clinical data
Clinical data
Questionnaire
22 severe asthmatics
22/22 omalizumab (+)


[36]
Airway-wall thickness
Eosinophils count
Bronchial biopsies 11 severe asthmatics
11/11 omalizumab (+)

[31]
Bronchial smooth muscle proteins Bronchial biopsies 8 severe astmatics
8/8 omalizumab (+)
[37]
  1. ET-1 endothelin-1, FeNO fractional exhaled nitric oxide, ECP eosinophil cationic protein, FEV1 forced expired volume in 1 s, EB exhaled breath, EBC exhaled breath condensate, RANTES/CCL5 regulated on activation, normal T cell expressed and secreted/chemokine (C–C motif) ligand-5, PEF peak expiratory flow, CalvNO estimated alveolar nitric oxide concentration, CT computerized tomography, ACT asthma control test.